insights_auto
Why is ABVX down 4,16%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
84,15 €
arrow_downward
-4,16%(-3,65) 1D
1 հոկ, 17:39:38 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
86,90 €
High
87,30 €
Low
83,20 €
Mkt. cap
7,58 մլրդ
Avg. vol.
152,86 հզր
Volume
138,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
Open
86,90 €
High
87,30 €
Low
83,20 €
Mkt. cap
7,58 մլրդ
Avg. vol.
152,86 հզր
Volume
138,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
News stories
From web sources and news partners
Fox Business
·
1 ժամ առաջ
October could be a huge month for the stock market. Here's why.
Simply Wall Street
·
11 րոպե առաջ
Why Is F5 (FFIV) Back As An IDC MarketScape Leader?
TradingView
·
1 ժամ առաջ
Evernorth clears shareholder vote ahead of Nasdaq debut with 473M XRP treasury
Yahoo Finance
·
2 ժամ առաջ
Why this analyst sees 15% upside for the S&P 500
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
Sector-
Websiteabivax.com